Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | STAT3 | P40763 | 17/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3047375 | 0.93 | MAPT (0.45) | ALDH1A1LMNAMAPTSTAT3MAPK1 | |
| SCHEMBL3050861 | 0.90 | ALDH1A1 (0.44) | ALDH1A1LMNAMAPTSTAT3SMN1; SMN2 | |
| SCHEMBL3066289 | 0.86 | SCN9A (0.47) | ALDH1A1LMNAMAPTSTAT3MAPK1 | |
| SCHEMBL3060076 | 0.86 | STAT3 (0.46) | STAT3SCN9A | |
| SCHEMBL3060046 | 0.85 | STAT3 (0.44) | STAT3SCN9A | |
| SCHEMBL3050880 | 0.84 | SETD7 (0.39) | ALDH1A1LMNAMAPTMAPK1HTT | |
| SCHEMBL3050877 | 0.84 | SETD7 (0.39) | ALDH1A1LMNAMAPTMAPK1HTT | |
| SCHEMBL3055560 | 0.83 | LMNA (0.44) | ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL3067543 | 0.81 | STAT3 (0.63) | STAT3 | |
| SCHEMBL3058206 | 0.80 | MET (0.39) | ALDH1A1LMNAMAPTSTAT3SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551999-B2 | Heterocyclic compound and pharmaceutical composition thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2207773-B1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMA CO LTD (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
| EP-2207773-A2 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009057811-A2 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | COL1A1, COL2A1, COL14A1 | ALDH1A1 741/4885LMNA 1184/4885MAPT 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.